HealthResearcher Discusses New PFIC Therapy Targeting Disease Mechanism
Dr. Hisamitsu Hayashi, a researcher behind a new therapy for Progressive Familial Intrahepatic Cholestasis (PFIC), discusses a treatment targeting the bile salt export pump (BSEP). Current US-approved PFIC drugs mainly address pruritus, but this therapy focuses on the underlying disease mechanism. Dr. Hayashi shares insights on diagnosis, clinical data, and future developments in PFIC treatment.
HCPLive·




